Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025

oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]

AI Summary: Eli Lilly has announced the return of renowned scientist Carolyn Bertozzi to its Board of Directors. Her comeback underscores the company’s commitment to a research‐intensive strategy and reinforces its focus on cutting–edge oncology and other therapeutic innovations.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Eli Lilly and Nvidia Launch $1B AI Co‑Innovation Lab / 4 months

Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 3 months

Eli Lilly buys Orna to sprint into in‑vivo CAR‑T therapeutics / 3 months

First-in-human trial primes immune system to accept donor livers / 6 wks

Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 7 wks

Keratin 16 restrains skin inflammation and may guide treatments / 7 wks

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes / 2 months